Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| growth hormone derivatives | 5042 | 82030-87-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
was MH (1997-2002), demoted; an analog of the synthetic human growth hormone (human somatropin) in which a methionyl amino-acid residue is added. It may be produced in bacteria from recombinant DNA. It is used in therapy for growth hormone deficiency. Do not confuse somatrem with sometribove (methionyl bovine somatotropin).
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 17, 1985 | FDA | GENENTECH |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Clear cell renal cell carcinoma | 275.07 | 101.58 | 36 | 194 | 1245 | 42619860 |
| Lymphoproliferative disorder | 240.93 | 101.58 | 36 | 194 | 3271 | 42617834 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Clear cell renal cell carcinoma | 301.94 | 84.55 | 38 | 180 | 2718 | 110586363 |
| Lymphoproliferative disorder | 265.36 | 84.55 | 38 | 180 | 7180 | 110581901 |
| Renal cell carcinoma | 110.59 | 84.55 | 18 | 200 | 7512 | 110581569 |
None
| Source | Code | Description |
|---|---|---|
| ATC | H01AC02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pituitary dwarfism | indication | 367460001 | DOID:0060870 |
| Growth retardation | indication | 444896005 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Growth hormone receptor | Membrane receptor | AGONIST | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
| ID | Source |
|---|---|
| CU8D464EDW | UNII |
| D05884 | KEGG_DRUG |
| 4019548 | VUID |
| N0000147652 | NUI |
| 4019548 | VANDF |
| C0143083 | UMLSCUI |
| CHEBI:749435 | CHEBI |
| CHEMBL1201620 | ChEMBL_ID |
| 5487805 | PUBCHEM_CID |
| DB09098 | DRUGBANK_ID |
| 5528 | INN_ID |
| C447442 | MESH_SUPPLEMENTAL_RECORD_UI |
| 202986 | RXNORM |
| 3666 | MMSL |
| 5500 | MMSL |
| d00576 | MMSL |
| 002105 | NDDF |
| 109052005 | SNOMEDCT_US |
| 125578008 | SNOMEDCT_US |
None